Selected cases, organized by what the science needed to produce. Not a portfolio. A proof set.
CD388 — a drug-Fc conjugate arraying zanamivir for single-dose, strain-agnostic influenza prophylaxis.
At a pivotal Phase 2b readout, a genuinely new drug class could read as “just another flu shot.”
An investor communication strategy that reframed the readout as an investable value proposition.